You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Adjusted annual indirect costs ($) due to short-term disabilities by type of comorbidity

From: Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database

Comorbidity No. of patients with comorbidity Adjusted costs for patients with comorbidity No. of patients without comorbidity Adjusted costs for patients without comorbidity Incremental adjusted costs Lower 95% CL Upper 95% CL
Psoriatic arthritis 516 1346.7 5362 860.0 403.5 −44.9 852.0
Cardiovascular disease 543 1635.0 5335 828.2 817.8 314.1 1321.6
Depression 355 2112.7 5523 825.0 996.6 431.6 1561.6
Anxiety 267 1344.2 5611 881.8 267.8 −300.9 832.8
Diabetes 570 1816.3 5308 804.7 928.0 400.1 1456.0
Hyperlipidemia 1624 1163.2 4254 803.3 356.5 70.0 643.0
Hypertension 1373 1319.0 4505 775.9 576.5 233.7 919.3
Obesity 189 2293.4 5689 856.6 1195.1 16.1 2374.1
Cerebrovascular disease 81 2501.5 5797 880.4 1333.1 −181.1 2847.2
Peripheral vascular disease 64 1912.2 5814 891.6 994.9 −789.2 2779.0
Any of the abovea 3123 1191.9 2755 575.0 614.1 390.0 838.2
  1. Note: The adjusted costs were predicted based on the model results using the recycled prediction method [38] for patients with and without comorbidities using the study sample. The incremental adjusted costs are differences in the adjusted costs between patients with and without comorbidities. The 95% CLs were calculated using bootstrapping method for both direct and indirect costs
  2. aAny of the above comorbidities means if patients have any of the either comorbidities mentioned above